Long-Acting Injectable Antipsychotics in Schizophrenia and Comorbid Substance Use Disorder: A Systematic Review of the Literature
Highlights What are the main findings? Nine studies involving 2062 patients with schizophrenia and comorbid substance use disorder (SUD) were included, with follow-up periods ranging from 6 months to 3 years. Several studies reported favorable clinical outcomes with long-acting injectable (LAI) antipsychotics, but the...